Can Ebola Vaccine Keep Virus From Taking Root?

The transcript discusses the World Health Organization's (WHO) initial reluctance to use an experimental Ebola vaccine from GlaxoSmithKline during an outbreak, focusing instead on containment. As the outbreak worsened, WHO reconsidered and sought the vaccine. The transcript covers the vaccine's development, testing, and potential availability, alongside international efforts to control the virus. It also addresses ethical concerns and challenges in distributing the vaccine, especially to healthcare workers, and the risk of the virus becoming endemic in West Africa.

What was the initial stance of the WHO regarding the use of GlaxoSmithKline's Ebola vaccine?

• They had no knowledge of the vaccine.

• They immediately approved its use.

• They were interested but focused on containment.

• They rejected it due to safety concerns.

Why did the WHO eventually reconsider the use of the Ebola vaccine?

• The outbreak was contained successfully.

• The vaccine was proven effective in humans.

• The outbreak spiraled out of control.

• Other countries demanded its use.

What is a major concern if the Ebola virus becomes endemic in West Africa?

• It could lead to a global pandemic.

• It would be impossible to develop a vaccine.

• It would require permanent quarantine measures.

• It could spread to other regions over time.

Who are prioritized to receive the Ebola vaccine first according to the ethical considerations discussed?

• The general public.

• Children and elderly people.

• Health care workers.

• Politicians and leaders.

What is the expected timeline for the availability of Ebola vaccine doses from GlaxoSmithKline and Johnson & Johnson?

• By the end of 2015.

• By mid-2015.

• By early 2015.

• By the end of 2014.